Clinical effect of sacubitril valsartan in the treatment of elderly patients with chronic severe heart failure and its influence on cardiac function
Objective To study the clinical effect of sacubitril valsartan in the treatment of elderly patients with chronic severe heart failure and its influence on cardiac function.Methods A total of 100 elderly patients with chronic severe heart failure admitted from January to December 2022 were selected as the research objects.According to different treatment methods,the patients were divided into control group(48 cases)and study group(52 cases).The control group received conventional drug treatment,and the study group was treated with sacubitril valsartan on the basis of the control group.The clinical efficacy,cardiac function indexes,myocardial injury indexes,neuroendocrine indexes and quality of life were compared between the two groups.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)in the study group was greater than that in the control group,and the left ventricular mass index(LVMI)and left ventricular end-diastolic diameter(LVEDD)were smaller than those in the control group(P<0.05).After treatment,the levels of creatine kinase isoenzymes-MB(CK-MB),cardiac troponin Ⅰ(cTnⅠ)and N-terminal pro-brain natriuretic peptide(NT-proBNP)in the study group were lower than those in the control group(P<0.05).After treatment,the levels of aldosterone(ALD),angiotensin Ⅱ(Ang Ⅱ)and norepinephrine(NE)in the study group were lower than those in the control group(P<0.05).After treatment,the scores of emotion,body and others in the study group were lower than those in the control group(P<0.05).Conclusion The sacubitril valsartan in the treatment of elderly patients with chronic severe heart failure has definite clinical effect,which can significantly improve the cardiac function of patients,delay the progression of heart failure and promote the quality of life.